Avelumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Avelumab: From Cutaneous Neuroendocrine Carcinoma to Human Herpesvirus 8-Related Tumor
One-Sentence Summary
Avelumab was originally used to treat cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). The TxGNN model predicts it may be effective for human herpesvirus 8-related tumor, but no clinical trials and no publications were found in the data compiled for this report, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cutaneous neuroendocrine carcinoma (taken from the knowledge-graph indication record; the Singapore licence has no indication text) |
| Predicted New Indication | Human herpesvirus 8-related tumor |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Avelumab is known to be an immune checkpoint inhibitor that blocks PD-L1. This is general background and not drawn from the compiled data.
Human herpesvirus 8 (HHV-8)-related tumors, such as Kaposi sarcoma, are virus-driven and may express PD-L1. Blocking PD-L1 is therefore biologically plausible. Merkel cell carcinoma is also a virus-associated tumor in many cases, which may partly explain the model's link between the two. However, no trials or literature were provided to test this idea, so it remains a hypothesis.
Other Predictions in the Top 10
All ten predictions have scores above 99.9% and none has clinical trial or literature support. They differ greatly in plausibility:
| Rank | Predicted Disease | Score | Assessment |
|---|---|---|---|
| 1 | Human herpesvirus 8-related tumor | 99.97% | Plausible (virus-driven, may express PD-L1); no evidence |
| 2 | Middle ear neuroendocrine tumor | 99.97% | Extrapolated from another neuroendocrine tumor; uncertain |
| 3 | Malignant cutaneous granular cell skin tumor | 99.97% | Only shares the cutaneous tumor context; no checkpoint rationale |
| 4 | Ectomesenchymoma | 99.97% | No clear mechanistic rationale |
| 5 | Adenosine deaminase deficiency | 99.95% | Metabolic immunodeficiency; likely a model artifact |
| 6 | Reticular dysgenesis | 99.94% | No plausible link; likely a model artifact |
| 7 | Immunoerythromyeloid hypoplasia | 99.94% | No evident link; likely a model artifact |
| 8 | Non-severe combined immunodeficiency | 99.92% | No rationale; immune-related adverse events are a safety concern |
| 9 | Prostatic urethra urothelial carcinoma | 99.92% | Better grounded: avelumab is approved as maintenance therapy for urothelial carcinoma; site-specific evidence needed |
| 10 | Kidney pelvis sarcomatoid transitional cell carcinoma | 99.91% | Better grounded: upper-tract urothelial variant, often PD-L1 positive; variant-specific evidence needed |
Ranks 9 and 10 (the urothelial carcinoma subsites) are the best-grounded candidates and are marked "Research Question", meaning a targeted search is warranted. Ranks 5 to 8 are immunodeficiencies, where the high scores most likely reflect network proximity rather than real biology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15672P | BAVENCIO Concentrate for Solution for Infusion 200mg/10mL (MERCK SERONO SA) | Injection, solution, concentrate | Not stated in the data compiled for this report |
This is the only licence on record, and it is a valid single-ingredient product. It is an injectable form.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (PD-L1 inhibitor), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: Three Major-level interactions were identified, all with immunomodulatory agents:
- Lenalidomide
- Pomalidomide
- Thalidomide
For warnings and contraindications, please refer to the package insert. The package insert has not yet been retrieved.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for human herpesvirus 8-related tumor is based only on the TxGNN model score (L5), with no registered trials or publications. Several other top predictions, especially the immunodeficiency diseases, appear to be model artifacts.
To proceed, the following is needed:
- Retrieve the HSA package insert to obtain warnings, contraindications and the approved indication (currently a blocking gap for safety screening)
- Obtain mechanism of action data from DrugBank
- Search for trials and literature on avelumab in HHV-8-related tumors, such as Kaposi sarcoma
- Run targeted searches for the urothelial carcinoma subsites (prostatic urethra, kidney pelvis sarcomatoid), which are the best-grounded alternatives
- Assess route compatibility and similarity to the original indication, both currently pending
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.